This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Our results provide important insights into the anti-inflammatory mechanism of action of β5i-inhibitors which currently hold the promise as a novel therapy for autoinflammatory diseases.
| INTRODUC TI ON
Proteasomes are specialized complexes degrading poly-ubiquitylated proteins in eukaryotic cells. Proteasome-dependent proteolysis occurs in the central 20S core particle, a four stacked ring of seven subunits each. 1 The two inner rings are made of constitutive catalytic β-subunits β1c, β2c and β5c which have caspase-like, trypsin-like and chymotrypsin-like activity, respectively. 2 In cells of hematopoietic origin or upon receipt of inflammatory signals such as IFN-γ, nascent proteasome complexes incorporate the inducible catalytic subunits β1i (LMP2), β2i (MECL-1), and β5i (LMP7) instead of the constitutive counterparts in the core particle to form the immunoproteasome. [3] [4] [5] In particular monocytes and lymphocytes have been shown to contain immunoproteasome proteins. [6] [7] [8] It is believed that cells upregulate immunoproteasomes to maintain protein homeostasis to cope with cellular stress thereby altering antigen processing for the generation of major histocompatibility (MHC) class I-restricted epitopes. 9, 10 Since the approval of proteasome inhibitor Bortezomib many inhibitors targeting specific catalytic subunits have been developed. 2, 11 Targeting the active β5i site of the immunoproteasome in particular appears a promising strategy for the treatment of autoimmune disorders. 9, 12 Bortezomib targets the chymotrypsin-like catalytic subunits β5c and β5i and, in addition, inhibits the other active sites β1c/β1i and β2c/β2i at higher concentrations. 13, 14 Its applicability in inflammatory disorders is limited by neurotoxicity observed in clinical use. 15 However, the irreversible immunoproteasome selective inhibitor ONX 0914 (formerly designated PR-957), shows 20-to 40-fold selectivity to β5i over its constitutive counterpart β5c 16 and attenuated disease progression in experimental autoimmune and inflammatory models. [16] [17] [18] [19] Because of its selectivity for β5i inhibition, ONX 0914 is supposed to exhibit an improved side effect profile compared to rather unselective immunoproteasome inhibition. In human PBMCs, ONX 0914 treatment blocked endotoxininduced cytokine production and polyclonal-mediated IFN-γ release in vitro 16 suggesting that β5i regulates inflammatory cytokine production in human cells and that its function goes beyond MHC class I-related antigen processing.
Naïve β5i-deficient animals do not show an overt phenotype in the absence of pathogen challenge aside from an overall reduced MHC class I surface expression. 20, 21 Interestingly, the recently discovered human type I IFN-driven proteasome-associated autoinflammatory syndromes (PRAAS) are caused by loss-of-function mutations in PSMB8, the gene encoding β5i, and/or other proteasome subunits [22] [23] [24] [25] which results in an accumulation of oxidized and poly-ubiquitylated proteins in patient tissues. 22, 24 Cytokine-induced oxidative stress can lead to accumulation of poly-ubiquitylated-proteins and their clearance by immunoproteasomes is essential for preservation of cell viability. 10 Hence, it remains of high interest for the development of novel therapeutic agents targeting immunoproteasome catalytic subunits to study the relation of inhibiting immunoproteasome function in human cells, cellular viability, and cytokine production.
In the present study, we addressed this concept by characterizing cytokine production along with viability of human peripheral blood-derived immune cells in the presence of proteasome inhibitors Bortezomib and ONX 0914. We demonstrate that TLR-dependent and TCR-triggered cytokine release was suppressed in PBMC cultures upon pharmacological inhibition of the immunoproteasome.
Human monocyte subsets, however, were rapidly depleted in the presence of Bortezomib or ONX 0914 at least in part via apoptosis induction.
| MATERIAL S AND ME THODS

| Compounds
Bortezomib (Velcade ® , PS-341) was purchased from Synchem (Felsberg, Germany). ONX 0914 (formerly PR957) or (2S)-3-(4-
propanoyl]amino]propanamide was synthesized as previously described in WO2007149512.
| Enzymatic activity of human (immuno) proteasomes
Human purified immunoproteasome and constitutive proteasomes were kindly provided by Dr. Marcus Groettrup, University of Constance, and isolated from human cell lines LCL721.174
(containing constitutive proteasome), and LCL721.145 (containing immunoproteasome) as described. 26 Compounds were serially 
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| Human PBMC and whole blood cultures
| Human T cell cultures
Human PBMCs were cultured in cell culture medium in the presence of recombinant CMVpp65 (Miltenyi, Bergisch Gladbach, Germany) and compounds at a final concentration of 0.1% DMSO. After 7 days, supernatants were harvested and IFN-γ cytokine content was determined 
| Data analysis
All data are expressed as mean ± SEM. Analysis was performed with
GraphPad Prism software version 6. IC 50 values were determined from three parameter fit graphs.
| RE SULTS
| Selective inhibition of β5i catalytic subunit associated chymotrypsin-like activity by ONX 0914 but not Bortezomib
To study the role of immunoproteasome in human PBMC function, we synthesized two inhibitor compounds, Bortezomib as a panproteasome inhibitor 27 and ONX 0914 as a β5i-selective inhibitor 16 and evaluated enzymatic inhibition of the immunoproteasome using subunit-specific fluorogenic substrates in vitro.
Subunit selectivity of the generated compounds ( Figure 1A Figure S1 ).
In summary, Bortezomib inhibited chymotrypsin-like activity of both cPS and iPS preparations suggesting broad-spectrum proteasome inhibitory potential, whereas ONX 0914 selectively inhibited the chymotrypsin-like activity associated with β5i enzymatic activity.
| Immunoproteasome inhibitors suppress cytokine production but largely affect cellular viability
Earlier reports demonstrated that selective immunoproteasome inhibitors inhibit TLR-triggered pro-inflammatory cytokine production in human PBMCs. 16 However, since proteasome inhibition might lead to protein aggregate formation and apoptosis induction, 10 we investigated TLR-induced cytokine production as well as viability of cells in the presence of Bortezomib and ONX 0914.
Bortezomib potently inhibited TNF ( In sum, pan-proteasome inhibition as well as specific pharmacological inhibition of β5i immunoproteasome activity in human primary immune cells led to potent inhibition of TLR-induced cytokine production and TCR-triggered IFN-γ release. However, both inhibitors strongly affected cell viability in a similar potency range regardless of a continuous or short-term drug exposure regimen.
| Immunoproteasome inhibitors induce apoptosis in human PBMCs
To further elucidate how immunoproteasome inhibitors decreased cell viability, we investigated the cells by flow cytometry using the apoptosis marker Annexin V. 
| Rapid depletion of human monocyte subsets by immunoproteasome inhibitors
The observation that TLR-induced cytokine production and 
| D ISCUSS I ON
Our results indicate that the pan-proteasome inhibitor Bortezomib and the β5i-selective inhibitor ONX 0914 are highly potent in suppressing human TLR-induced cytokine production and TCR-triggered to be determined whether impairment in alternative signal transduction pathways following immunoproteasome inhibition might result into aberrant IL-23 expression. LPS activation of human immune cells can not only trigger myeloid differentiation marker 88 (MyD88) but also Toll-interleukin-1 receptor (TIR) domain-containing adaptorinducing interferon-β (TRIF)-dependent pathways leading to interferon regulatory factor 3 (IRF3) activation, 35 which is dependent on ubiquitination processes 36 and leads to type I interferon, and also IL-23 production. 37, 38 Our study confirmed that the β5i-selective inhibitor ONX 0914
and Bortezomib potently inhibited human T cell activation induced by polyclonal activation (previously demonstrated by others 16, 39, 40 ) and by antigen-specific stimulation. 41 Presentation of CMVpp65-derived epitopes to responder T cells is dependent on antigen-presenting cells and hence, the cytotoxicity induced in monocytes as observed in this study upon immunoproteasome inhibition, will largely impact the CMVpp65-induced IFN-γ production. Reduced IFN-γ, IL-17A, and IL-6 production of ONX 0914-treated human PBMCs stimulated with heat-killed C.albicans was reported previously, 41 profile observed with these inhibitors. More importantly, some mutations in PSMB8 described to induce PRAAS not only attenuate the chymotrypsin-like activity of the immunoproteasome but also inhibit assembly or maturation of the immunoproteasome. 59 Nevertheless, based on the enzymatic inhibitory profile, it is to be expected that ONX 0914 and analogs might inhibit different cell types in vivo 41 leading to different toxicity profile as reported for pan-proteasome inhibitor Bortezomib.
| CON CLUS ION
Here, we demonstrated that Bortezomib and ONX 0914 as a β5-selective immunoproteasome inhibitor induced human immune cell death along with anti-inflammatory efficacy in human PBMC cultures in vitro. Although our study provides mechanistic insights for these immunoproteasome inhibitors, the development of non-covalent and/or reversible β5-selective inhibitors as well as improved subunitselective immunoproteasome inhibitors will further help to elucidate the therapeutic potential of the immunoproteasome.
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